Clinical trial
Safety and Efficacy of Nonacog Beta Pegol (N9-GP) in Previously Untreated…
NCT02141074 · Novo Nordisk A/S, Industry · Completed
Key facts
| NCT number | NCT02141074 |
|---|---|
| Title | Safety and Efficacy of Nonacog Beta Pegol (N9-GP) in Previously Untreated Patients With Haemophilia B |
| Official title | An Open-label Single-arm Multicentre Non-controlled Phase 3 a Trial Investigating Safety and Efficacy of Nonacog Beta Pegol (N9-GP) in Prophylaxis and Treatment of Bleeding Episodes in Previously Untreated Patients With Haemophilia B (FIX Activity Below or Equal to 2 Percent) |
| Acronym | paradigm™6 |
| Lead sponsor | Novo Nordisk A/S, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Congenital Bleeding Disorder, Haemophilia B |
| Intervention type | Drug |
| Interventions | nonacog beta pegol |
| Enrollment | 54 |
| Start date | Jul 2, 2014 |
| Primary completion | Oct 27, 2022 |
| Completion | Oct 27, 2022 |
| First posted | May 19, 2014 |
| Last update posted | Dec 23, 2025 |
| Countries | Algeria, Argentina, Australia, Austria, Bulgaria, Canada, France, Germany, Greece, Israel, Italy, Japan and 12 more |
At a glance
- 100–999 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: